Clinical trial · Interventional
Topical 2% Povidone-Iodine Gel in Verruca Vulgaris
A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo Gel (no Povidone-Iodine) | Drug | — | UNRESOLVED |
| VBP-245 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- VBP-245
- description
- Topical 2% Povidone-Iodine Gel
- interventionNames
- Drug: VBP-245
- type
- PLACEBO_COMPARATOR
- label
- Control
- description
- Placebo Gel (no Povidone-Iodine)
- interventionNames
- Drug: Placebo Gel (no Povidone-Iodine)
Primary outcomes (1)
- measure
- Decrease in wart diameter (mm)
- timeFrame
- 12 weeks
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
Show eligibility criteria text
Inclusion Criteria: * Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study. * Male or female ≥ 8 years old. * Subject has a clinical diagnosis of verruca vulgaris (common warts). * Subject has up to 6 warts located on the trunk or extremities Exclusion Criteria: * Subject has clinically atypical warts on the trunk or extremities. * Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.) * Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform wart identified as a wart for study treatment.
References
Publications (0)
Data not yet available